Global Allergy Vaccine Market Size, Share, and COVID-19 Impact Analysis, By Type (Subcutaneous Immunotherapy and Sublingual Immunotherapy), By Application (Allergic Rhinitis, Allergic Asthma and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 - 2035

Global Allergy Vaccine Market Size Forecasts to 2035

• The Global Allergy Vaccine Market Size Was Estimated at USD 1.64 Billion in 2024
• The Market Size is Expected to Grow at a CAGR of around 9.61% from 2025 to 2035
• The Worldwide Allergy Vaccine Market Size is Expected to Reach USD 4.50 Billion by 2035
• Asia Pacific is expected to grow the fastest during the forecast period.

The global allergy vaccine market size was worth around USD 1.64 billion in 2024 and is predicted to grow to around USD 4.50 billion by 2035 with a compound annual growth rate (CAGR) of 9.61% from 2025 to 2035. The growing prevalence of allergic diseases and rising government initiatives are driving the allergy vaccine market worldwide.

Market Overview

The allergy vaccine market refers to the market of allergy immunotherapy encompassing the development, manufacturing, and distribution of vaccines designed for treating allergic conditions by desensitizing the patient's immune system to specific allergens. Allergy vaccines, also known as allergy shots, are a long-term treatment option for allergy symptoms that are very effective and have no long-term side effects. There are upsurging advancements in personalized medicine, where allergy treatments are tailored to individual patient profiles, improving the overall patient outcomes. Escalating allergy prevalence in densely populated nations such as China and India, along with the expanding healthcare infrastructure, increasing per-capita spending, and an influx of international players, are several factors that are responsible for escalating the market growth opportunities.

Report Coverage

This research report categorizes the allergy vaccine market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the allergy vaccine market. Recent market developments and competitive strategies such as expansion, type launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the allergy vaccine market.

Driving Factors

The growing prevalence of allergic diseases is responsible for propelling the allergy vaccine market. Asthma and AD continue to cause significant morbidity with increased prevalence and incidence cases worldwide. There are serious public health concerns, including allergic reactions to drugs and vaccines, which can cause wide and varied reactions, such as immunoglobulin E (IgE)-mediated reactions and other immune-mediated. Vaccine allergies can contribute to vaccine hesitancy, creating a public health issue. Thus, increasing government initiatives are supporting market growth for allergy vaccines.

Restraining Factors

The increased treatment costs, long treatment durations, and strict regulatory pathways, along with the limited insurance coverage, are challenging the allergy vaccine market. Further, the lack of allergen extracts, restricting the development of allergy immunotherapy, is hindering the market growth for allergy vaccines.

Market Segmentation

The allergy vaccine market share is classified into type, application, and distribution channel.

• The subcutaneous immunotherapy segment dominated the allergy vaccine market in 2024 and is projected to grow at a substantial CAGR during the forecast period.

Based on the type, the allergy vaccine market is divided into subcutaneous immunotherapy and sublingual immunotherapy. Among these, the subcutaneous immunotherapy segment dominated the allergy vaccine market in 2024 and is projected to grow at a substantial CAGR during the forecast period. It involves the administration of controlled doses of allergens through subcutaneous routes. The increasing healthcare spending and trend towards personalized medicine, enhancing the accessibility and effectiveness of allergy management solutions, is driving the market in the subcutaneous immunotherapy segment.

• The allergic rhinitis segment dominated the allergy vaccine market in 2024 and is anticipated to grow at a significant CAGR during the forecast period.

Based on the application, the allergy vaccine market is divided into allergic rhinitis, allergic asthma, and others. Among these, the allergic rhinitis segment dominated the allergy vaccine market in 2024 and is anticipated to grow at a significant CAGR during the forecast period. Allergy vaccines, also known as allergen immunotherapy, can be an effective treatment for allergic rhinitis (hay fever), gradually desensitizing the immune system to specific allergens, reducing the severity of allergic reactions over time. An increasing allergy cases owing to environmental factors, including lifestyle changes and genetic predispositions, necessitating innovative treatment solutions like allergy vaccines, is contributing to propel the market in the allergic rhinitis segment.

• The hospital pharmacies segment dominated the allergy vaccine market in 2024 and is anticipated to grow at a significant CAGR during the forecast period.

Based on the distribution channel, the allergy vaccine market is divided into hospital pharmacies, retail pharmacies, and online pharmacies. Among these, the hospital pharmacies segment dominated the allergy vaccine market in 2024 and is anticipated to grow at a significant CAGR during the forecast period. Allergy vaccines are typically distributed through a structured process involving the preparation, dispensing, and administration under stringent protocols, ensuring patient safety and efficacy of the treatment.

Regional Segment Analysis of the Allergy Vaccine Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the allergy vaccine market over the predicted timeframe.

North America is anticipated to hold the largest share of the allergy vaccine market over the predicted timeframe. The presence of strong healthcare infrastructure, like established hospitals, laboratories, and medical personnel with expertise in allergy and immunology, is driving the allergy vaccine market. Further, the prevalence of allergy and advanced healthcare infrastructure are contributing factors to allergy vaccine market.

Asia Pacific is expected to grow at a rapid CAGR in the allergy vaccine market during the forecast period. Exposure to air pollution and environmental allergies, with growing urbanization and industrialization, is driving the allergy vaccine market in the region. The expanding sector for allergy immunotherapy that uses comparable immunotherapy techniques for treating allergies is contributing to the market growth for allergy vaccine.

Europe is anticipated to hold a significant share of the allergy vaccine market during the projected timeframe. The rising prevalence of allergic conditions such as allergic rhinitis, asthma, and food allergies is significantly driving the regional allergy vaccine market. The upsurging demand for allergy vaccines, owing to the demand for effective and long-lasting treatment alternatives with the increased prevalence of allergies, is promoting the market growth.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the allergy vaccine market, along with a comparative evaluation primarily based on their type of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes type development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• NIOX Group plc
• DBV Technologies
• Stallergenes Greer
• Allergy Therapeutics
• Novartis AG
• Merck and  Co., Inc.
• ALK
• HAL Allergy B.V.
• HollisterStier Allergy
• Aimmune Therapeutics
• Biomay AG
• Arryait Corporation (ARYC)
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs) 

Recent Development

• In February 2024, Roche announced that the U.S. Food and Drug Administration (FDA) had approved Xolair (omalizumab) for the reduction of allergic reactions, including anaphylaxis, that may occur with accidental exposure to one or more foods in adult and pediatric patients aged 1 year and older with IgE-mediated food allergy.
• In October 2023, French-Canadian pharmaceutical firm Angany announced that it had received clearance to initiate its first clinical trial investigating a vaccine intended to treat allergy to cats.

Market Segment

This study forecasts revenue at the global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the allergy vaccine market based on the below-mentioned segments: 

Global Allergy Vaccine Market, By Type

• Subcutaneous Immunotherapy
• Sublingual Immunotherapy

Global Allergy Vaccine Market, By Application

• Allergic Rhinitis
• Allergic Asthma
• Others

Global Allergy Vaccine Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Allergy Vaccine Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa